<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003540</url>
  </required_header>
  <id_info>
    <org_study_id>98-030</org_study_id>
    <secondary_id>CDR0000066594</secondary_id>
    <secondary_id>NCI-G98-1474</secondary_id>
    <nct_id>NCT00003540</nct_id>
  </id_info>
  <brief_title>Gemcitabine in Treating Women With Metastatic Breast Cancer Previously Treated With Doxorubicin and Paclitaxel</brief_title>
  <official_title>Phase II Study of Gemcitabine in the Treatment of Patients With Metastatic Breast Cancer Previously Treated With Adriamycin and Taxol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating women with&#xD;
      metastatic breast cancer previously treated with doxorubicin and paclitaxel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the objective response rate to gemcitabine in women with metastatic breast&#xD;
           cancer previously treated with two to four chemotherapy regimens, including doxorubicin&#xD;
           and paclitaxel.&#xD;
&#xD;
        -  Characterize the nature of toxicity of gemcitabine in this patient population.&#xD;
&#xD;
        -  Determine the response duration to gemcitabine in this patient population.&#xD;
&#xD;
      OUTLINE: Patients receive gemcitabine IV over 30 minutes once weekly for 3 consecutive weeks&#xD;
      (days 1, 8, and 15) followed by 1 week of rest. Treatment continues every 4 weeks in the&#xD;
      absence of disease progression or unacceptable toxic effects.&#xD;
&#xD;
      Patients are followed until death.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 14-30 patients will be accrued for this study within 13 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1998</start_date>
  <completion_date type="Actual">November 2002</completion_date>
  <primary_completion_date type="Actual">November 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic breast cancer&#xD;
&#xD;
          -  Bidimensionally measurable disease&#xD;
&#xD;
               -  No bone scan abnormalities alone&#xD;
&#xD;
               -  Lytic lesions in conjunction with bone scan abnormalities allowed&#xD;
&#xD;
               -  No pure blastic bone metastases&#xD;
&#xD;
               -  No pleural or peritoneal effusions&#xD;
&#xD;
               -  No previously irradiated lesions&#xD;
&#xD;
          -  Must have received 2-4 prior chemotherapy regimens, including paclitaxel and&#xD;
             doxorubicin, for breast cancer&#xD;
&#xD;
          -  Brain metastases allowed if other measurable disease exists&#xD;
&#xD;
               -  No uncontrolled or life threatening brain lesions&#xD;
&#xD;
          -  No carcinomatous meningitis&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  AST/ALT no greater than 5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Calcium no greater than 11.0 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No history of other malignancy except carcinoma in situ of the cervix or curatively&#xD;
             treated nonmelanoma skin cancer&#xD;
&#xD;
          -  No other serious medical illnesses, including severe infection and severe malnutrition&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior hormonal therapies for stage IV disease and/or adjuvant therapy allowed&#xD;
&#xD;
          -  At least 3 weeks since prior hormonal therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior radiotherapy to greater than 30% of the marrow bearing bone&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy to the only measurable lesion&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
          -  No concurrent surgery to the only measurable lesion&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent nonprotocol treatment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Violante E. Currie, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>September 24, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2003</study_first_posted>
  <last_update_submitted>June 24, 2013</last_update_submitted>
  <last_update_submitted_qc>June 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

